A point mutation in the MET oncogene abrogates metastasis without affecting transformation

Silvia Giordano, Alberto Bardelli, Zhu Zhen, Sylvie Menard, Carola Ponzetto, Paolo M. Comoglio

Research output: Contribution to journalArticle

Abstract

The MET oncogene encodes the tyrosine kinase receptor for hepatocyte growth factor/scatter factor (HGF), known to stimulate invasive growth of epithelial cells. MET is overexpressed in a significant percentage of human cancers and is amplified during the transition between primary tumors and metastasis. To investigate whether this oncogene is directly responsible for the acquisition of the metastatic phenotype, we exploited a single-hit oncogenic version of MET, able to transform and to confer invasive and metastatic properties to nontumorigenic cells, both in vitro and in nude mice. We mutagenized the signal transducer docking site of Met (Y1349VHVX3Y1356VNV), which has the uncommon property of binding and activating multiple src homology region 2 (SH2)-containing intracellular effectors. Notably, a point mutation (H1351 → N) increased the transforming ability of the oncogene but abolished its metastatic potential. This mutation duplicates the Grb2 binding site, super-activating the Ras pathway and preventing the binding of the other intracellular transducers. Complementation in trans with another nonmetastatic mutant (N1358 → H), recruiting all the transducers downstream to Met except Grb2, rescued the invasive-metastatic phenotype. It is concluded that the metastatic potential of the MET oncogene relies on the properties of its multifunctional docking site, and that a single point mutation affecting signal transduction can dissociate neoplastic transformation from metastasis.

Original languageEnglish
Pages (from-to)13868-13872
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume94
Issue number25
DOIs
Publication statusPublished - Dec 9 1997

Fingerprint

Oncogenes
Point Mutation
Transducers
Neoplasm Metastasis
Hepatocyte Growth Factor
Phenotype
Receptor Protein-Tyrosine Kinases
Nude Mice
Signal Transduction
Neoplasms
Epithelial Cells
Binding Sites
Mutation
Growth

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

A point mutation in the MET oncogene abrogates metastasis without affecting transformation. / Giordano, Silvia; Bardelli, Alberto; Zhen, Zhu; Menard, Sylvie; Ponzetto, Carola; Comoglio, Paolo M.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 94, No. 25, 09.12.1997, p. 13868-13872.

Research output: Contribution to journalArticle

@article{666646102fb74fda9d3d77ed67cc67bb,
title = "A point mutation in the MET oncogene abrogates metastasis without affecting transformation",
abstract = "The MET oncogene encodes the tyrosine kinase receptor for hepatocyte growth factor/scatter factor (HGF), known to stimulate invasive growth of epithelial cells. MET is overexpressed in a significant percentage of human cancers and is amplified during the transition between primary tumors and metastasis. To investigate whether this oncogene is directly responsible for the acquisition of the metastatic phenotype, we exploited a single-hit oncogenic version of MET, able to transform and to confer invasive and metastatic properties to nontumorigenic cells, both in vitro and in nude mice. We mutagenized the signal transducer docking site of Met (Y1349VHVX3Y1356VNV), which has the uncommon property of binding and activating multiple src homology region 2 (SH2)-containing intracellular effectors. Notably, a point mutation (H1351 → N) increased the transforming ability of the oncogene but abolished its metastatic potential. This mutation duplicates the Grb2 binding site, super-activating the Ras pathway and preventing the binding of the other intracellular transducers. Complementation in trans with another nonmetastatic mutant (N1358 → H), recruiting all the transducers downstream to Met except Grb2, rescued the invasive-metastatic phenotype. It is concluded that the metastatic potential of the MET oncogene relies on the properties of its multifunctional docking site, and that a single point mutation affecting signal transduction can dissociate neoplastic transformation from metastasis.",
author = "Silvia Giordano and Alberto Bardelli and Zhu Zhen and Sylvie Menard and Carola Ponzetto and Comoglio, {Paolo M.}",
year = "1997",
month = "12",
day = "9",
doi = "10.1073/pnas.94.25.13868",
language = "English",
volume = "94",
pages = "13868--13872",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "25",

}

TY - JOUR

T1 - A point mutation in the MET oncogene abrogates metastasis without affecting transformation

AU - Giordano, Silvia

AU - Bardelli, Alberto

AU - Zhen, Zhu

AU - Menard, Sylvie

AU - Ponzetto, Carola

AU - Comoglio, Paolo M.

PY - 1997/12/9

Y1 - 1997/12/9

N2 - The MET oncogene encodes the tyrosine kinase receptor for hepatocyte growth factor/scatter factor (HGF), known to stimulate invasive growth of epithelial cells. MET is overexpressed in a significant percentage of human cancers and is amplified during the transition between primary tumors and metastasis. To investigate whether this oncogene is directly responsible for the acquisition of the metastatic phenotype, we exploited a single-hit oncogenic version of MET, able to transform and to confer invasive and metastatic properties to nontumorigenic cells, both in vitro and in nude mice. We mutagenized the signal transducer docking site of Met (Y1349VHVX3Y1356VNV), which has the uncommon property of binding and activating multiple src homology region 2 (SH2)-containing intracellular effectors. Notably, a point mutation (H1351 → N) increased the transforming ability of the oncogene but abolished its metastatic potential. This mutation duplicates the Grb2 binding site, super-activating the Ras pathway and preventing the binding of the other intracellular transducers. Complementation in trans with another nonmetastatic mutant (N1358 → H), recruiting all the transducers downstream to Met except Grb2, rescued the invasive-metastatic phenotype. It is concluded that the metastatic potential of the MET oncogene relies on the properties of its multifunctional docking site, and that a single point mutation affecting signal transduction can dissociate neoplastic transformation from metastasis.

AB - The MET oncogene encodes the tyrosine kinase receptor for hepatocyte growth factor/scatter factor (HGF), known to stimulate invasive growth of epithelial cells. MET is overexpressed in a significant percentage of human cancers and is amplified during the transition between primary tumors and metastasis. To investigate whether this oncogene is directly responsible for the acquisition of the metastatic phenotype, we exploited a single-hit oncogenic version of MET, able to transform and to confer invasive and metastatic properties to nontumorigenic cells, both in vitro and in nude mice. We mutagenized the signal transducer docking site of Met (Y1349VHVX3Y1356VNV), which has the uncommon property of binding and activating multiple src homology region 2 (SH2)-containing intracellular effectors. Notably, a point mutation (H1351 → N) increased the transforming ability of the oncogene but abolished its metastatic potential. This mutation duplicates the Grb2 binding site, super-activating the Ras pathway and preventing the binding of the other intracellular transducers. Complementation in trans with another nonmetastatic mutant (N1358 → H), recruiting all the transducers downstream to Met except Grb2, rescued the invasive-metastatic phenotype. It is concluded that the metastatic potential of the MET oncogene relies on the properties of its multifunctional docking site, and that a single point mutation affecting signal transduction can dissociate neoplastic transformation from metastasis.

UR - http://www.scopus.com/inward/record.url?scp=0031471232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031471232&partnerID=8YFLogxK

U2 - 10.1073/pnas.94.25.13868

DO - 10.1073/pnas.94.25.13868

M3 - Article

C2 - 9391119

AN - SCOPUS:0031471232

VL - 94

SP - 13868

EP - 13872

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 25

ER -